Surveillance for small renal masses appears safe at 10 years

"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.

Treatment with the Optilume BPH System resulted in significant, immediate symptomatic and functional improvements in patients with BPH, according to 12-month data from the PINNACLE study.

“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.

“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.